Home・Aktien・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Open

BrancheGesundheitswesen

258.52 9.88

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

231.82

Max

263.86

Schlüsselkennzahlen
By Trading Economics
Einkommen	262M -15M
Verkäufe	1.6M 996M
EPS	2.06
Gewinnspanne	-1.486
Angestellte	18,300
EBITDA	-135M 64M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	-1.67% downside

Dividenden
By Acuity
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	2.8B 11B
Vorheriger Eröffnungskurs	248.64
Vorheriger Schlusskurs	258.52

Nachrichtenstimmung

By Acuity

10%

90%

14 / 340 Ranking in Healthcare

Charles River Laboratories International Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Charles River Laboratories International Inc Prognose

Kursziel

By TipRanks

-1.67% Nachteil

12-Monats-Prognose

Durchschnitt 230.2 USD -1.67%

Hoch 265 USD

Tief 213 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Charles River Laboratories International Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Charles River Laboratories International Inc – Dist abgegeben haben.

Stimmung

By Acuity

14 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.